Bill Text: TX HB3086 | 2025-2026 | 89th Legislature | Introduced
Bill Title: Relating to requirements for pharmaceutical drug manufacturers to report prescription drug costs.
Sponsorship: Partisan Bill (Republican 1)
Status: (Introduced) 2025-03-20 - Referred to Public Health [HB3086 Detail]
Download: Texas-2025-HB3086-Introduced.html
| 89R8229 JTZ-F | ||
| By: Oliverson | H.B. No. 3086 | |
|
|
||
|
|
||
| relating to requirements for pharmaceutical drug manufacturers to | ||
| report prescription drug costs. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Section 441.0051, Health and Safety Code, is | ||
| amended to read as follows: | ||
| Sec. 441.0051. ANNUAL REPORT. (a) Not later than the 15th | ||
| day of each calendar year, a pharmaceutical drug manufacturer shall | ||
| submit a report to the department stating the current wholesale | ||
| acquisition cost information for the United States Food and Drug | ||
| Administration-approved prescription drugs sold in or into this | ||
| state by that manufacturer. | ||
| (b) For a prescription drug with a wholesale acquisition | ||
| cost increase of 40 percent or more over the drug's wholesale | ||
| acquisition cost in the preceding three calendar years or 15 | ||
| percent or more in the preceding calendar year, a pharmaceutical | ||
| drug manufacturer shall include in the annual report required under | ||
| Subsection (a): | ||
| (1) information on whether the prescription drug is a | ||
| brand name drug or generic version of a brand name drug; | ||
| (2) a statement on each factor that caused the | ||
| increase in the wholesale acquisition cost and an explanation of | ||
| the impact of each factor on the cost; | ||
| (3) aggregate, research, and development costs as | ||
| filed with United States Securities and Exchange Commission on Form | ||
| 10-K for the most recent calendar year for which final audit data is | ||
| available; | ||
| (4) the name of each of the manufacturer's | ||
| prescription drugs the United States Food and Drug Administration | ||
| approved in the previous three calendar years; and | ||
| (5) the name of each of the manufacturer's | ||
| prescription drugs that lost patent exclusivity in the United | ||
| States in the previous three calendar years. | ||
| (c) The information a pharmaceutical drug manufacturer | ||
| submits to the department under Subsections (a) and (b) must be | ||
| consistent with the information the manufacturer includes in the | ||
| manufacturer's annual consolidated report filed with the United | ||
| States Securities and Exchange Commission on Form 10-K or any other | ||
| public disclosure. | ||
| SECTION 2. Section 441.0054, Health and Safety Code, is | ||
| amended to read as follows: | ||
| Sec. 441.0054. PUBLICATION OF COST INCREASE INFORMATION. | ||
| Not later than the 60th day after receipt of the report submitted | ||
| under Section 441.0051 [ |
||
| publish the required cost increase information [ |
||
| Internet website. | ||
| SECTION 3. Section 441.0102(a), Health and Safety Code, is | ||
| amended to read as follows: | ||
| (a) The department shall [ |
||
| penalty against a person who violates this chapter or a rule adopted | ||
| under this chapter. | ||
| SECTION 4. Section 441.0053, Health and Safety Code, is | ||
| repealed. | ||
| SECTION 5. As soon as practicable after the effective date | ||
| of this Act, the executive commissioner of the Health and Human | ||
| Services Commission shall adopt rules necessary to implement the | ||
| changes in law made by this Act. | ||
| SECTION 6. This Act takes effect September 1, 2025. | ||
